U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2000


[ ]  TRANSITION  REPORT UNDER SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE
     ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO _____________


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

<TABLE>
<CAPTION>
<S>                                     <C>                                     <C>
DELAWARE                                                                                    98-0178784
(State or other jurisdiction of         (Primary Standard Industrial            (I.R.S. Employer Identification No.)
incorporation or organization)          Classification Code Number)
</TABLE>

 #3-1482 Springfield Road , Kelowna, British Columbia, Canada          V1Y 5V3
(Address of principal executive offices)                              (Zip Code)

                                 (250) 762-7552
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                              Stepp & Beauchamp LLP
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements  for the past 90 days.
[ ] Yes [ ]No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date.  As of August 31,  2000,  there were
5,965,699  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>


                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheet
$ United States

August 31, 2000 and May 31, 2000
(Unaudited - Prepared by Management)

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------
                                                          August 31,          May 31,
                                                               2000             2000
-------------------------------------------------------------------------------------

Assets

<S>                                                     <C>              <C>
Current assets
     Cash                                               $ 1,089,907      $   959,318
     Accounts receivable                                      7,373           21,070
     Prepaid expenses                                         3,425            6,820
-------------------------------------------------------------------------------------
                                                          1,100,705          987,208

Advances and deposits                                        75,395           42,000

Patent costs                                                 11,462           12,504

Capital assets (note 2)                                      48,655           47,124

-------------------------------------------------------------------------------------
                                                        $ 1,236,217      $ 1,088,836
=====================================================================================

Liabilities and Stockholders' Equity

Current liabilities
     Accounts payable and accrued liabilities           $    17,241      $    27,791

Redeemable preferred shares (note 3)                        301,727          301,727

Share subscriptions (note 4(b))                             134,290          185,513

Stockholders' equity
     Capital stock (note 4)                                   5,965            5,846
     Additional paid in capital                           2,589,966        2,201,056
     Deficit accumulated during the development stage    (1,846,276)      (1,666,401)
     Accumulated other comprehensive income                  33,304           33,304
-------------------------------------------------------------------------------------
                                                            782,959          573,805
-------------------------------------------------------------------------------------
                                                        $ 1,236,217      $ 1,088,836
=====================================================================================
</TABLE>

See accompanying notes to financial statements

On behalf of the Board:

_____________________  Director

_____________________  Director


                                       2
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Loss
$ United States

For the three months ended August 31, 2000 and 1999
(Unaudited - Prepared by Management)

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
                                                 From Inception
                                               (March 17, 1997)              2000             1999
                                             to August 31, 2000
--------------------------------------------------------------------------------------------------

<S>                                                 <C>               <C>              <C>
Expenses
     Advertising                                    $    14,135       $       --       $        --
     Amortization                                        51,315             4,755            4,042
     Automotive                                          49,139             4,632            2,786
     Consulting fees                                    151,549            27,322            8,078
     Conventions and seminars                             2,300             2,300               --
     Design plans                                        10,911                --               --
     Director's fees                                     21,528                --               --
     Foreign exchange loss (gain)                        15,251               (25)             829
     Freight                                              1,082             1,082
     Insurance                                           18,112             5,557               --
     Interest and bank charges                           10,724             1,833              795
     Legal and accounting                               199,947            25,864           16,739
     Licences, fees and dues                              4,341                --               --
     Management fees                                    426,698            60,434           34,404
     Office and administration                          205,763            30,020           15,446
     Product development                                 29,119             2,535               --
     Promotion and entertainment                         16,332               527              453
     Prospectus and share issuance                        3,350             3,350               --
     Rent                                               133,218            18,176           10,265
     Repairs and maintenance                              2,381                65               --
     Storage                                                467               467               --
     Telephone and utilities                             42,396             2,409            2,633
     Travel                                              54,424             1,720              647
     Video production                                    26,783               511               --
     Write down of inventory                             55,734                --               --
     Write down of product rights and
       patent costs                                     374,128                --               --
--------------------------------------------------------------------------------------------------
                                                      1,921,127           193,534           97,117

--------------------------------------------------------------------------------------------------
Loss from operations                                 (1,921,127)         (193,534)         (97,117)

Other income
     Interest income                                     74,851            13,659            2,884
--------------------------------------------------------------------------------------------------
                                                     (1,846,276)         (179,875)         (94,233)


--------------------------------------------------------------------------------------------------
Net loss                                            $(1,846,276)      $  (179,875)     $   (94,233)
--------------------------------------------------------------------------------------------------


Loss per share                                                        $     (0.03)     $     (0.02)

Weighted average shares used                                            5,909,401        5,529,198
==================================================================================================
</TABLE>

See accompanying notes to financial statements


                                       3
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Cash Flows
$ United States

For the three months ended August 31, 2000 and 1999
(Unaudited - Prepared by Management)

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
                                                    From inception
                                                   (March 17, 1997)               2000              1999
                                                to August 31, 2000
---------------------------------------------------------------------------------------------------------

<S>                                                     <C>                   <C>            <C>
Operating activities
   Net loss                                             $(1,846,276)          (179,875)      $   (94,233)

   Items not involving cash
     Amortization                                            51,315              4,755             4,042
     Gain on sale of capital asset                           (2,659)                --                --
     Write down of inventory                                 55,734                 --                --
     Write down of product rights                           374,128                 --                --

   Changes in non-cash working capital
     Accounts receivable                                     (7,373)            13,697            (6,323)
     Prepaid expenses                                        (3,425)             3,395                 1
     Accounts payable and accrued liabilities                17,241            (10,550)            2,319
     Inventory purchases                                    (55,734)                --                --
---------------------------------------------------------------------------------------------------------
                                                         (1,417,049)          (168,578)          (94,194)
Financing
     Issuance of capital stock                            1,742,687            203,516                --
      Proceeds from subscriptions for shares                987,534            134,290            90,956
---------------------------------------------------------------------------------------------------------
                                                          2,730,221            337,806            90,956
Investing
     Acquisition of capital assets                          (96,963)            (5,244)               --
     Acquisition of product rights                          (90,577)                --                --
     Proceeds on disposition of capital asset                 6,189                 --               138
     Advances and deposits                                  (75,395)           (33,395)               --
---------------------------------------------------------------------------------------------------------
                                                           (256,746)           (38,639)              138

Foreign currency translation adjustment                         177                 --                --
Other comprehensive income                                   33,304                 --                --
---------------------------------------------------------------------------------------------------------
Increase (decrease) in cash                               1,089,907            130,589            (3,100)

Cash, beginning of period                                        --            959,318           346,646

---------------------------------------------------------------------------------------------------------
Cash, end of period                                     $ 1,089,907        $ 1,089,907       $   343,546
---------------------------------------------------------------------------------------------------------

Supplementary information:
   Interest paid                                        $        --        $        --       $        --
   Income taxes paid                                             --                 --                --
Non-cash financing and investing activities:
   Issuance of redeemable preferred shares
     for product rights                                     309,677                 --                --
   Common shares issued for conversion of
     share subscriptions                                $   248,244        $   185,513       $    62,731
---------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements


                                       4
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
$ United States

For the period from inception on March 17, 1997 to August 31, 2000

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------
                                                                               Deficit
                                     Capital Stock                         Accumulated     Accumulated
                                ----------------------      Additional      During the           Other           Total
                                  Number                       Paid in     Development   Comprehensive   Stockholders'
                                of Shares       Amount         Capital           Stage          Income          Equity
----------------------------------------------------------------------------------------------------------------------

<S>                             <C>          <C>            <C>            <C>             <C>                <C>
Common shares issued                    3    $        --    $        --    $        --     $        --

Comprehensive income:
  Loss                                 --             --             --       (138,272)             --        (138,272)
  Foreign currency translation         --             --             --             --          13,582          13,582
----------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)            --             --             --       (138,272)         13,582        (124,690)
----------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                   3              1             --       (138,272)         13,582        (124,689)

Common shares issued
  net of share issue costs      2,410,944          2,410        472,355             --              --         474,765

Common shares issued
  net of shares issue costs     3,072,300          3,072        601,928             --              --         605,000

Comprehensive income:
  Loss                                 --             --             --       (293,239)             --        (293,239)
  Foreign currency translation         --             --             --             --          (7,294)         (7,294)
----------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)            --             --             --       (293,239)         (7,294)       (300,533)
----------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998           5,483,247          5,483      1,074,283       (431,511)          6,288         654,543

Common shares issued
  net of share issue costs         36,300             36         96,726             --              --          96,762

Comprehensive income:
  Loss                                 --             --             --       (726,055)             --        (726,055)
  Foreign currency translation         --             --             --             --          17,038          17,038
----------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)            --             --             --       (726,055)         17,038        (709,017)
----------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999           5,519,547          5,519      1,171,009     (1,157,566)         23,326          42,288

Common shares issued
  net of share issue costs        307,610            308        967,335             --              --         967,643

Common shares issued for
  conversion of share
  subscriptions                    19,302             19         62,712             --              --          62,731

Comprehensive income:
  Loss                                 --             --             --       (508,835)             --        (508,835)
  Foreign currency translation         --             --             --             --           9,978           9,978
----------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)            --             --             --       (508,835)          9,978        (498,857)
----------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2000           5,846,459    $     5,846    $ 2,201,056    $(1,666,401)    $    33,304     $   573,805
======================================================================================================================
</TABLE>


                                       5
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
(continued)
$ United States

For the period from inception on March 17, 1997 to August 31, 2000

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------
                                                                               Deficit
                                     Capital Stock                         Accumulated     Accumulated
                                ----------------------      Additional      During the           Other           Total
                                  Number                       Paid in     Development   Comprehensive   Stockholders'
                                of Shares         Amount       Capital           Stage          Income          Equity
----------------------------------------------------------------------------------------------------------------------

<S>                              <C>          <C>            <C>            <C>             <C>            <C>
Balance, May 31, 2000            5,846,459    $     5,846    $ 2,201,056    $(1,666,401)    $    33,304    $   573,805

Common shares issued
  net of share issue costs          62,159             62        203,454             --              --        203,516

Common shares issued for
  conversion of share
  subscriptions                     57,081             57        185,456             --              --        185,513

Comprehensive income:
  Loss                                  --             --             --       (179,875)             --       (179,875)
  Foreign currency translation          --             --             --             --              --             --
----------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --             --             --       (179,875)             --        209,154
----------------------------------------------------------------------------------------------------------------------
Balance, Aug 31, 2000            5,965,699    $     5,965    $ 2,589,966    $(1,846,276)    $    33,304    $   782,959
----------------------------------------------------------------------------------------------------------------------
</TABLE>





                                       6
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

L.O.M. Medical International Inc. was incorporated on March 17, 1997 under the
General Corporation Laws of Delaware. It conducts research and development on
new products in the medical field and has filed a patent application on a
retractable syringe. Operations effectively commenced on June 1, 1997.

1.   Significant accounting policies:

     a)   Going concern

          These financial statements have been prepared on the going concern
          basis, which assumes the realization of assets and liquidation of
          liabilities in the normal course of business. As shown in the
          consolidated financial statements, to date, the Company has generated
          no revenues and has accumulated a deficit since inception of
          $1,846,276. This factor, among others raises substantial doubt about
          the Company's ability to continue as a going concern. The Company's
          ability to continue as a going concern is dependent on its ability to
          generate future profitable operations and receive continued financial
          support from its stockholders and other investors.

          Management's plans with respect to generating future profitable
          operations include future sales of the retractable syringe as well as
          additional funding from stockholders in the form of additional share
          subscriptions.

     b)   Basis of presentation and consolidation

          The consolidated financial statements include the accounts of the
          Company and its 96% owned subsidiary, L.O.M. Laboratories Inc.

     c)   Translation of financial statements

          The Company's subsidiary, L.O.M. Laboratories Inc. operates in Canada
          and its operations are conducted in Canadian currency.

         The method of translation applied is as follows:

          i)   Monetary assets and liabilities are translated at the rate of
               exchange in effect at the balance sheet date, being US $1.00 per
               Cdn $1.47

          ii)  Non-monetary assets and liabilities are translated at the rate of
               exchange in effect at the transaction date.

          iii) Revenues and expenses are translated at the exchange rate in
               effect at the transaction date.

          iv)  The net adjustment arising from the translation is included in
               accumulated other comprehensive income.

     d)   Patent costs

          Patent costs relate to amounts paid to acquire the rights to produce
          and distribute products as well as the costs associated with patent
          applications.


                                       7
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 3
$ United States

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     d)   Patent costs (continued)

          These costs are being amortized on a straight-line basis over five
          years.

     e)   Capital assets

          Capital assets are recorded at cost. Amortization is provided using
          the following methods and annual rates which are intended to amortize
          the cost of the assets over their estimated useful life:

          ----------------------------------------------------------------------
          Asset                                       Method              Rate
          ----------------------------------------------------------------------

          Leasehold improvements               Straight-line               20%
          Computer software                    Straight-line              100%
          Equipment                        Declining balance               30%
          Furniture and fixtures           Declining balance               20%
          ----------------------------------------------------------------------


     f)   Income taxes

          The Company accounts for income taxes by the asset and liability
          method. Under the asset and liability method, deferred tax assets and
          liabilities are recognized for the future tax consequences
          attributable to differences between the financial statement carrying
          amounts of existing assets and liabilities and their respective tax
          bases and operating loss and tax credit carryforwards. Deferred tax
          assets and liabilities are measured using enacted tax rates expected
          to apply to taxable income in the years in which those temporary
          differences are expected to be recovered or settled. The effect on
          deferred tax assets and liabilities of a change in tax rates is
          recognized in income in the period that includes the enactment date.

     g)   Management estimates

          The preparation of financial statements in conformity with generally
          accepted accounting principles in the United States of America
          requires management to make estimates and assumptions that affect the
          reported amounts of assets and liabilities and disclosures of
          contingent assets and liabilities at the date of the financial
          statements and the reported amounts of revenues and expenses during
          the reporting period. Actual results could differ from those
          estimates.

     h)   Financial instruments

          The fair values of the Company's cash, accounts receivable and
          accounts payable and accrued liabilities approximate their carrying
          values due to the relatively short periods to maturity of the
          instruments. It is not possible to arrive at a fair value for
          redeemable preferred shares as a public market for this stock does not
          exist. The maximum credit risk exposure for all financial assets is
          the carrying amount of those assets.


                                       8
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 4
$ United States

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     i)   Loss per share

          Loss per share has been calculated using the weighted average number
          of common shares outstanding during the period.

2.   Capital assets:

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
                                                                              August 31,         May 31,
                                                                                    2000            2000
--------------------------------------------------------------------------------------------------------
                                                           Accumulated          Net book        Net book
                                               Cost       amortization             value           value
--------------------------------------------------------------------------------------------------------
     <S>                                      <C>              <C>               <C>             <C>
     Leasehold improvements                   $27,919          $12,563           $15,356         $16,752
     Computer software                          5,446            1,778             3,668           4,192
     Equipment                                 29,844           15,311            14,533          12,588
     Furniture and fixtures                    23,354            8,256            15,098          13,592
--------------------------------------------------------------------------------------------------------
                                              $86,563          $37,908           $48,655         $47,124
--------------------------------------------------------------------------------------------------------
</TABLE>

3.   Redeemable preferred shares:

     The Company's subsidiary has redeemable preferred shares outstanding as
     follows:

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------
                                                                               August 31,        May 31,
                                                                                     2000           2000
--------------------------------------------------------------------------------------------------------

    <S>                                                                           <C>            <C>
     Issued:
         4,000 Class C preferred  shares with a par
           value of $100 Cdn redeemable at $110.16 Cdn per share
           at the option of the  holder.  Each share is entitled to a fixed
           non-cumulative dividend at the rate of 9% per annum
           payable at such times as determined by the Directors.                  301,727        301,727
--------------------------------------------------------------------------------------------------------
</TABLE>

4.   Capital stock:

     a)   Authorized:

          50,000,000 Common shares with a par value of $.001 each 5,000,000
          Preferred shares with a par value of $.001 each

     b)   Share subscriptions:

          Subsequent to August 31, 2000, the Company issued 67,734 common shares
          at $3.25 per share for net proceeds of $134,290 which were received
          prior to August 31, 2000.


                                       9
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 6
$ United States

(Unaudited - Prepared by Management)
--------------------------------------------------------------------------------

4.   Capital stock (continued):

     c)   Stock option plan:

          1,000,000 common shares of the Company are reserved for issuance upon
          exercise of stock options. As at August 31, 2000, no stock options
          have been granted.

5.   Related party transactions:

     During the period the Company entered into the following transactions with
     related parties:

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------
                                                                           2000            1999
-----------------------------------------------------------------------------------------------

     <S>                                                               <C>             <C>
     Legal and accounting fees paid to a director                      $  8,403        $    464
     Management fees paid to president                                   30,608          34,404
     Office and administration fees paid to president's spouse            9,182           9,000
     Office and administration fees paid to an individual
       related to the president                                           5,322           4,389
     Management fees to a company controlled by the president            20,000               -
     Rent paid to a company controlled by the president                  14,140           4,605

-----------------------------------------------------------------------------------------------
</TABLE>

     These transactions are in the normal course of operations and are measured
     at the exchange amount of consideration established and agreed to by the
     related parties.

6.   Commitments:

     The Company is obligated to make future lease payments for it's offices as
     follows:

         2001                                                    $  14,590
         2002                                                    $  19,453
         2003                                                    $  19,453
         2004                                                    $  19,453
         2005                                                    $  19,453

7.   Income taxes:

     At August 31, 2000, the Company had a net operating loss carryforward for
     United States income tax purposes of approximately $1,800,000. The net
     operating loss expires in increments beginning in 2008. No amount has been
     reflected on the balance sheet for future income taxes as any future income
     tax asset has been fully offset by a valuation allowance.



                                       10
<PAGE>


Item 2.  Management's Discussion and Analysis or Plan of Operation

Development of the Company. L.O.M. Medical International Inc., a Delaware
corporation ("Company"), was incorporated in the State of Delaware on March 17,
1997. Our executive offices are located at #3-1482 Springfield Road, Kelowna, B.
C., Canada V1Y 5V3. The Company's telephone number is 250.762.7552.

For purposes of clarification, anytime the symbol "US" is used within this
Annual Report of Form 10-KSB, it refers to the currency of the United States.
Anytime the symbol "CDN" is used, it refers to the currency of Canada.

Business of the Company. The Company was originally incorporated for the purpose
of researching and developing health care products. Our goal is to become an
innovator and provider of a retractable syringe ("Syringe") and related products
and technologies to the health care market. We also hope to successfully market
and distribute our line of eye care products. We have successfully patented and
licensed products in seventy countries including the United States and Canada.
We envision that we will be able to develop new and improved products and
provide the health care industry with better, safer products throughout the
world.

The Syringe. We anticipate that the Syringe will change standard disposal
methods for used syringes. We have developed a product designed to function as a
standard hypodermic syringe that is safer to the caregiver or health care
worker. We believe that the Syringe's unique design will allow health care
providers to avoid direct contact with used needles. The Syringe is covered by
United States Patent No. 5,868,713 dated February 9, 1999, and international
patents have been filed in 24 different countries.

Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to automatically retract the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again. The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe will be produced in standard industry sizes from 1CC to 20 CC,
inclusive. We intend to promote the Syringe as a safer and less risk-oriented
instrument for hospital staff and health care workers. We are optimistic that
doctors, nurses, and health care workers alike will recognize and appreciate the
safety features of the Syringe because of its ease of "use-and-disposal" and its
unique "contaminate-prevention" characteristics.

We anticipate that the products and technologies developed by us will be offered
to distributors on a worldwide basis, with an initial emphasis in Canada and the
United States. We hope that new product and technology ideas will be generated
through active dialogues among us, our customers, and our network of scientific
advisors, as well as through active participation in national and international
conferences, and reviews of selected scientific literature.

Our management interacts with a network of scientific advisors within the
industry, including members of academic institutions, as well as potential
customers. We anticipate that these interactions will enable us to identify the
specialized needs of those potential customers and to provide innovative and
commercially acceptable products and technologies. At this time, our
relationship with scientific advisors and academic institutions is limited to an
advisory relationship. We currently perform all of our own research and
development. We do not currently use the services of third parties to conduct
any of our research and development.

We anticipate that we will be testing the Syringe in conjunction with teaching
universities in Canada, Britain, and other constituents of the United Kingdom.

The Lens-O-Matic. We have invented and developed an insertion and storage device
for contact lenses (the "Lens-O-Matic") which is an ideal medical method of
handling and inserting contact lenses. We have developed the following
components and solutions that will be used together with the Lens-O-Matic
insertion and storage system:

     o    a medical inserter that will remove contact lenses in a medical
          emergency situation for use by hospital medical staff and paramedics;

     o    disposable and replacement inserter ends;

     o    additional storage cups and caps; and

     o    all soaking and disinfecting solutions that are to be used with the
          Lens-O-Matic inserter.


                                       11
<PAGE>


The Lens-O-Matic is designed so that the practitioner will no longer have direct
hand or finger contact with the contact lens when fitting the patient. We
believe that the design of the Lens-O-Matic will reduce the risk of
contamination and infection to the patient. We have developed a liquid cleaner
for the Lens-O-Matic that quickly cleans contact lenses. We have obtained Food
and Drug Administration Approval ("FDA") for the Lens-O-Matic product. We have
also completed market testing and believe that the Lens-O-Matic was well
received at the A.O.A. convention in Montreal, Canada, where approximately
30,000 units were distributed to opticians, optometrists and pharmacies. We have
also completed the formulation of our contact lens solutions and copyrights
covering these products have been registered. We have also completed the design
and labeling of the Lens-O-Matic package. We believe that our eye-care products
are ready for marketing and distribution.

The target markets for the distribution for the Lens-O-Matic product include,
but are not necessarily limited to:

     o    hospitals and clinics, including Shippert Medical of Englewood,
          Colorado ("Shippert"), Cross Mark Sales & Marketing of Plano, Texas;
          and

     o    optometrists and opticians including, Health Care Insights of Edison,
          New Jersey.

Mind Your Own Skin. We are currently in the first phase of licensing agreements
with the owners of "Mind Your Own Skin". We have invested over $100,000.00 to
date to pay for licensing agreements and patents in North America. We intend to
manufacture and distribute the product in the future.

Business of the Company's Subsidiary. There has been no activity in the
subsidiary this quarter. For the forseeable future the subsidiary will be
inactive.

Our Future Capital Requirements. We will require additional cash to implement
our business strategies, including cash for (i) payment of increased operating
expenses and (ii) further implementation of our business strategies. No
assurance can be given, however, that we will have access to the capital markets
in the future, or that financing will be available on acceptable terms to
satisfy our cash requirements to implement our business strategies. Our
inability to access the capital markets or obtain acceptable financing could
have a material adverse effect on our results of operations and financial
condition.

Our forecast of the period of time through which our financial resources will be
adequate to support our operations is a forward-looking statement that involves
risks and uncertainties, and actual results could vary as a result of a number
of factors.

We anticipate that we will need to raise additional capital over the next
several months in order to develop, promote, produce and distribute our proposed
products. Such additional capital may be raised through additional public or
private financings, as well as borrowings and other resources. To the extent
that additional capital is raised through the sale of equity or equity-related
securities, the issuance of such securities could result in dilution of our
stockholders. There can be no assurance that additional funding will be
available on favorable terms, if at all. If adequate funds are not available
within the next 12 months, we may be required to curtail our operations
significantly or to obtain funds through entering into arrangements with
collaborative partners or others that may require us to relinquish rights to
certain of our products that we would not otherwise relinquish. However, we
believe that we are poised to maintain our long-term liquidity.

We anticipate spending funds in excess if $500,000 over the next several months
in order to produce our syringe for testing purposes. During this period there
may be significant increases to our staffing levels. A portion of these
expenditures will include funds used for further research on the Syringe.

We are not currently producing commercial quantities of our products nor are we
currently supplying any services to any third parties. No assurance can be given
that we will, on a timely basis, be able to make the transition from
manufacturing testing quantities of the Syringe to commercial production
quantities successfully or be able to arrange for contract manufacturing. We
have produced 33,000 units of our eye care products which will be used for
demonstrations. As such, we have not inventoried the units but have expensed
them in prior financial statements. Our current production capacity does allow
for the production of commercial quantities of our eye care products. We believe
that we can increase our output to 150,000 units. We have a second set of dyes
designed that will have a 300,000 unit capacity which would allow the production
of a total of 450,000 units of our eye care products per month.

We anticipate that we will contract out the first two years of production of the
Syringe. At the end of the second year of production, we anticipate we will
engage in significant discussions regarding the potential for the construction
of our own production facility. We recognize that the construction of our own
production facility will be contingent upon us having reached our sales and
profit projections. We anticipate that we will present this issue for vote by
our Board of Directors


                                       12
<PAGE>


and shareholders. In this regard, we anticipate that we will locate our
production facilities in North America, specifically, the State of Washington,
due to its strategic location for penetration into the United States and
Canadian markets.

Our eye care products are currently produced in Canada. We own all of the
necessary injection molds. We contract out for the production of components
needed for the assembly and packaging of our eye care products. The actual
assembly and packaging will be subcontracted out at this time. All of our other
products, those either currently in production or the subject of future
production, will be produced on a contract basis through plants that are FDA
approved for production of medical products.

The manufacture of our products involves a number of steps and requires
compliance with stringent quality control specifications imposed by us and
various regulators. We may not be able to quickly replace our manufacturing
capacity if we were unable to use our manufacturing facilities as a result of a
fire, natural disaster (including earthquake), equipment failure or other
difficulty, or if such facilities are deemed not in compliance with the various
regulators' requirements and the non-compliance could not be rapidly rectified.
Our inability or reduced capacity to manufacture or have manufactured any of our
products would have a material adverse effect on our business and results of
operations.

We currently have access to the necessary production facilities to produce our
line of eye care products on a commercial basis. We have FDA approval to market
our line of eye care products in the United States. Also, as previously
discussed, we have the necessary Canadian approval to market our eye-care
products in Canada. We have commenced marketing the Lens-O-Matic in Canada as
well as the United States. Shippert Medical may be one of the companies that
will be marketing our eye care products in the United States as well as in
Canada. We have entered negotiations for a marketing and distribution contract
with Shippert Medical. The proposed contract has an initial two-year term with a
two-year renewal option.

Our products will be subject to numerous foreign government standards and
regulations that are continually being amended. Although we will endeavor to
satisfy foreign technical and regulatory standards, there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes thereto, or that it will be cost effective for us to redesign our
products to comply with such standards or regulations. Our inability to design
or redesign products to comply with foreign standards could have a material
adverse effect on our business, financial condition and results of operations.

The negotiations to set up a manufacturing plant in Ireland have not progressed
beyond the preliminary discussions discussed in our previous filings.

Our business and the business of our subsidiary will expose us to potential
product liability risks that are inherent in the testing, manufacturing and
marketing of medical products. We do not currently have product liability
insurance, and there can be no assurance that we will be able to obtain or
maintain such insurance on acceptable terms or, if obtained, that such insurance
will provide adequate coverage against potential liabilities. We face an
inherent business risk of exposure to product liability and other claims in the
event that the development or use of our technology or products is alleged to
have resulted in adverse effects. Such risk exists even with respect to those
products that are manufactured in licensed and regulated facilities or that
otherwise possess regulatory approval for commercial sale. There can be no
assurance that we will avoid significant product liability exposure. There can
be no assurance that insurance coverage will be available in the future on
commercially reasonable terms, or at all, or that such insurance will be
adequate to cover potential product liability claims or that a loss of insurance
coverage or the assertion of a product liability claim or claims would not
materially adversely affect our business, financial condition and results of
operations. While we have taken, and will continue to take, what we believes are
appropriate precautions, there can be no assurance that we will avoid
significant liability exposure. An inability to obtain product liability
insurance at acceptable cost or to otherwise protect against potential product
liability claims could prevent or inhibit the commercialization of our products.
A product liability claim could have a material adverse effect on our business,
financial condition and results of operations.

We believe that we are poised to maintain our long-term liquidity. This is based
upon cash flow projections prepared by us. We believe we have raised enough
capital to allow us to meet our financial obligations for a period of at least
twelve (12) months from August 31, 2000. However, our forecast for the period of
time through which our financial resources will be adequate to support our
operations is a forward-looking statement that involves risks and uncertainties,
and actual results could fail as a result of a number of factors.


                                       13
<PAGE>


Liquidity. We had cash resources of US$1,089,907.00 at August 31, 2000. At May
31, 2000, we had cash resources of US$959,318.00. At August 31, 2000, we had
total current assets of US$1,100,705.00 and total current liabilities of
US$17,241.00. At August 31, 2000, total current assets exceeded total current
liabilities by US$1,083,464.00. At May 31, 2000, we had total current assets of
US$987,208.00 and total current liabilities of US$27,791.00. At May 31, 2000,
total current assets exceeded total current liabilities by US$959,417.00. The
cash and equivalents constitute our present internal sources of liquidity.
Because we are not generating any significant revenues, our only external source
of liquidity is the sale of our capital stock.

Results of Operations. The Registrant has not yet realized any significant
revenue from operations. The net loss from operations from March 17, 1997
(inception) to August 31, 2000, was US$1,846,276.00. The net loss for the
3-month period ended August 31, 2000, was US$179,875.00. The net loss for the
12-month period ended May 31, 2000, was US$508,835.00. Such losses were
primarily the result of operational expenditures.

Item 2. Changes in Securities

We have offered to all shareholders of record, one warrant for every two shares
held by each shareholder. Each warrant entitles the holder of such warrant to
purchase one share of our common stock for $5.00 per share. Each warrant expires
by its own terms ninety (90) days after the first transaction in the Company's
shares occurs on the Over-the-Counter Bulletin Board.

Item 3.  Defaults Upon Senior Securities

None

Item 4.  Submission of Matters to Vote of Security Holders

None

Item 5.  Other Information

None

Item 6.  Exhibits and Reports on Form 8-K

None



                                       14
<PAGE>


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Dated:   September __, 2000               L.O.M. Medical International, Inc.


                                          By: /s/ John Klippenstein
                                             -----------------------------------
                                                  John Klippenstein
                                          Its:    President






                                       15